演題抄録

一般演題 (示説)

開催概要
開催回
第53回・2015年・京都
 

Recombinant human soluble thrombomodulin in cancer-induced disseminated intravascular coagulation

演題番号 : P52-5

[筆頭演者]
Koyama Takafumi:1 
[共同演者]
Hasegawa Yoriko:1、Hiramatsu Ayako:1、Fujisawa Takao:1、Hasegawa Akiko:1、Harada Yohei:1、Fujimoto Yumi:1、Hisamatsu Haruka:1、Saito Ayumi:1、Miura Daisuke:1、Oyama Yu:1

1:Medical Oncology, Kameda Medical Center

 

Background: Evidence of efficacy and safety, and especially mortality, related to recombinant human thrombomodulin (rh TM) treatment for cancer-induced disseminated intravascular coagulation (DIC) is not known. We undertook this study to describe results related to rh TM therapy.Methods: The medical record of all patients with solid tumors and cancer-induced DIC admitted to the oncology inpatient service of Kameda Medical Center between 2010 and 2014 were retrospectively reviewed. We abstracted the clinical and laboratory data of patients with a proven episode of cancer-induced DIC treated with rh TM. The diagnosis of DIC was based on the clinical condition, the underlying disease, and the laboratory results.Results: Six patients were included in this study. The median age was 56 years. One patient received rh TM twice and the others once. The duration of rh TM treatment was seven days for four patients, 14 days for two, and 21 days for one . Five patients did not receive any anticoagulant therapy at baseline. The International Society on Thrombosis and Hemostasis DIC scores at baseline were three for one patient, four for one, five for four and eight for one .Two patients experienced improvement in their DIC score. There were no thromboembolic or severe adverse events.Twenty-eight-day mortality was 50%. Conclusions: Rh TM appears to be a safe intervention in critically ill patients with cancer and suspected DIC. This study might provide a suggestion of efficacy supporting further development of this drug in cancer-induced coagulopathy

キーワード

臓器別:造血器・リンパ

手法別:支持療法

前へ戻る